Streetbeat News

CURLF

Curaleaf Holdings Inc

Employees

5,138

Industry

Medicinal and Botanical Manufacturing

Open

2.30

Mkt cap

1.6B

Volume

197K

High

2.30

P/E Ratio

-7.03

52-wk high

6.40

Low

2.08

Div yield

N/A

52-wk low

2.07

Germany is advancing its cannabis legalization with plans to open cannabis shops for scientific purposes, while the UK sees higher than expected medical marijuana sales. German shops aim to assess cannabis's impact on health and the black market, with Cannamedical and Demecan leading in Germany's medical cannabis market. Aurora and Tilray are notable international players. The UK's medical marijuana market is growing rapidly, with high per-patient consumption rates. Curaleaf is a key distributor in the UK, where private clinics are expanding treatment options.

Portfolio Pulse from Nina Zdinjak

May 13, 2024 | 2:33 pm

Beacon Securities and Needham reports highlight Q1 2024 financials for Curaleaf and Trulieve, respectively, with Curaleaf posting $339M in revenue and Trulieve $297.6M. Both companies are navigating regulatory changes positively, with Curaleaf focusing on strategic financial management and Trulieve on operational strengths and market opportunities. Legislative changes are expected to further benefit both companies.

Portfolio Pulse from Nicolás Jose Rodriguez

May 10, 2024 | 10:42 pm

Needham analyst Matt McGinley maintains a Buy rating on Curaleaf Holdings (OTC:CURLF) and raises the price target from $5.25 to $6.25.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 9:34 am

Trulieve Cannabis Corp. reported a Q1 revenue of $298 million, a 4% increase both sequentially and year-over-year, with a gross profit of $174 million. The company's net loss narrowed to $23 million, showing significant improvement in financial performance. Trulieve, a major backer of Florida's recreational cannabis ballot initiative, along with other top cannabis operators, is positioned for growth with the upcoming vote in November 2024.

Portfolio Pulse from Jelena Martinovic

May 09, 2024 | 12:49 pm

Marijuana stocks experienced significant movements on May 7, 2024, with notable gainers including Kaya Holdings, Elixinol Wellness, and CV Sciences, among others. Conversely, several companies faced declines, such as Target Group, Global Compliance, and SOL Global Investments. Notable NASDAQ and NYSE listed companies like Psychemedics, Urban-gro, cbdMD, Eastside Distilling, Canopy Growth, Tilray Brands, and Scotts Miracle-Gro also saw varied stock performance.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 8:30 pm

A report from Viridian Capital Advisors predicts a surge in M&A activity in the U.S. cannabis industry, particularly benefiting Tier 1 multi-state operators (MSOs) like Curaleaf Holdings, Green Thumb Industries, Trulieve Cannabis, and Cresco Labs. The report highlights a widening valuation gap between Tier 1 MSOs and smaller entities, alongside a differential in capital costs that favors larger MSOs. This environment is expected to lead to a period of consolidation, with equity increasingly used over cash for acquisitions due to the anticipation of Schedule 3 and sluggish banking reforms.

Portfolio Pulse from Nicolás Jose Rodriguez

May 06, 2024 | 11:42 pm

Cannabis stocks fell after reports emerged that the DEA Administrator Anne Milgram did not sign the order to reclassify cannabis as a Schedule III drug, contrary to expectations. This decision has halted the momentum of the Biden Administration's plan to acknowledge cannabis's medical benefits and its lower potential for abuse compared to Schedule I substances.

Portfolio Pulse from Adam Eckert

May 06, 2024 | 9:09 pm

Michael Berger, a cannabis stock expert at Benzinga, highlights the burgeoning opportunities in the cannabis sector, spurred by the DEA's decision to reclassify marijuana to Schedule III, signaling a bullish outlook for cannabis stocks. Berger emphasizes the importance of cautious investment in this volatile market, recommending a diversified approach and focusing on U.S. cannabis companies like Green Thumb Industries, Trulieve Cannabis, and Curaleaf Holdings, which exhibit strong financial metrics such as free cash flow, net income, and adjusted EBITDA.

Portfolio Pulse from Jelena Martinovic

May 03, 2024 | 5:17 pm

The DEA's rescheduling of cannabis to Schedule III has caused significant market volatility for multi-state operators (MSOs), with the MSO index initially surging by 25% and then dropping by 15%. Viridian Capital Advisors highlights the impact on MSOs' credit ratings and financial health, noting Green Thumb Industries' favorable deal, Trulieve's balanced risk-return profile, and the high yields but high risks for companies like Ascend Wellness, Verano, Cresco, and Curaleaf.

Portfolio Pulse from Nicolás Jose Rodriguez

May 03, 2024 | 3:57 pm

Following the DEA's announcement to reschedule cannabis, the market cap of major cannabis firms has seen significant changes. Curaleaf, Canopy, Tilray, Aurora, Green Thumb Industries, and Trulieve have experienced fluctuations in market capitalization since their public debuts. The total economic impact of regulated marijuana sales in the U.S. is expected to surpass $112.4 billion in 2024, with sales forecasted to reach $32.1 billion. Market cap growth varies among companies, with some experiencing decreases and others increases.

Portfolio Pulse from Nicolás Jose Rodriguez

May 01, 2024 | 6:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.